---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-147667"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2023-05-18T23:59:59+00:00"
generated_at: "2026-06-14T21:34:00.305867+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# President/COO Neil Klompas to leave Zymeworks June 30; CEO Galbraith becomes President

## Summary
- Departure of President and COO Neil Klompas effective June 30, 2023; consulting agreement through June 30, 2025.
- Separation includes $1M lump sum (24 months salary), continued benefits for 24 months, and stock vesting continuation.
- CEO Kenneth Galbraith appointed as President in addition to CEO and Chair roles, effective June 30.
- Galbraith has over 35 years of biotech executive experience; his compensation terms remain unchanged.
- Klompas had been with Zymeworks since 2007, serving as CFO, COO, and President.

## SEC filing metadata
- accession: 0001193125-23-147667
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2023-05-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000119312523147667/0001193125-23-147667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000119312523147667/d445207d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-147667
- JSON: https://secwatch.observer/filing/0001193125-23-147667.json
- Plain text: https://secwatch.observer/filing/0001193125-23-147667.txt

## Key facts
- Executive change
  Neil Klompas departed as President and Chief Operating Officer at Zymeworks Inc..
  - Action: step down
  - Role: President and Chief Operating Officer
  source text: On May 17, 2023, Zymeworks Inc. (the “Company”) and Mr. Neil Klompas, the Company’s President and Chief Operating Officer, mutually agreed to terms pursuant to which Mr. Klompas will step down as the Company’s President and Chief Operating Officer and separate from employment effective as of June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000119312523147667/0001193125-23-147667-index.htm
- Executive change
  Kenneth Galbraith was appointed as President at Zymeworks Inc..
  - Action: appointed
  - Role: President
  source text: the board of directors of the Company (the “Board”) appointed Mr. Kenneth Galbraith, the Company’s current Chief Executive Officer and Chair of the Board, as President of the Company to succeed Mr. Klompas in the role of President of the Company, effective as of the Separation Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000119312523147667/0001193125-23-147667-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.